ASGN’s former CEO Peter Dameris resigned amid scrutiny by federal prosecutors, company says

(exechange) — Calabasas, California, May 24, 2019 — Peter Dameris, former chief executive of ASGN, resigned amid scrutiny by federal prosecutors, the company says.

ASGN Inc. said in a regulatory filing published on Friday, May 24, 2019: “On April 24, 2019, the Company announced that Peter T. Dameris advised the Company’s Board of Directors that he would step down from his role as Chief Executive Officer of the Company effective April 30, 2019. The Company has been informed that Mr. Dameris’ resignation was the subject of negotiations between his counsel and the United States Attorney’s Office in Boston, Massachusetts, which has been investigating Mr. Dameris as a target in connection with the college admissions investigation.”

On April 24, 2019, ASGN had explained Peter Dameris’s departure from the CEO post as follows: “Mr. Dameris told the Company his youngest son, who has been battling acute myeloid leukemia for over a year, will require additional medical treatment. After a successful stem cell transplant in August 2018, Mr. Dameris’ son’s leukemia has returned, and the family is currently assisting their son with aggressive medical treatment.”